查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1320222

基因重組促血紅細胞生長素市場:各類型，各適應症，各最終用途，各國，各地區-2023-2030年的產業分析，市場規模，市場佔有率，預測

Recombinant Erythropoietin Market with COVID-19 Impact Analysis, By Type, By Indication, By End-Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年重組促紅血球生成素市場規模將達6,85128萬美元，2023年至2030年複合年增長率為2.1%

重組促紅血球生成素市場 - 市場動態：

慢性腎臟病 (CKD) 發生率的增加和對有效貧血治療的需求推動了市場需求

慢性腎病 (CKD) 發病率的增加以及對有效貧血治療的需求正在推動對重組促紅血球生成素 (rEPO) 的需求。rEPO，也稱為阿法促紅血球生成素，用於增加紅血球形成，緩解貧血症狀，並最大限度地減少輸血需求。由於老化和生活方式的改變，全球 CKD 盛行率不斷增加，醫療保健部門對 rEPO 作為治療 CKD 患者貧血的基本治療選擇的需求不斷增加。

重組促紅血球生成素市場 – 主要見解：

  • 根據研究分析師的分析，全球重組促紅血球生成素市場預計在預測期內（2023-2030 年）每年將以約 2.1% 的複合年增長率成長。
  • 由於慢性腎病 (CKD) 發病率的增加以及對有效貧血治療的需求，重組促紅血球生成素產業預計將以顯著的速度增長。
  • 按類型區隔，預計 Epoetin Alfa 將在 2022 年佔最大的市場佔有率。
  • 從跡象來看，癌症相關貧血是 2022 年的主要類型。
  • 按地區劃分，亞太地區將在 2022 年實現銷售額領先

重組紅血球生成素市場 - 區隔分析：

全球重組促紅血球生成素市場根據類型、適應症、最終用途和地區進行區隔。

市場依類型分為兩類：阿法依泊汀（epoetin alfa）、阿法達貝泊汀（darbepoetin alfa）。促紅血球生成素 α 是一種重組促紅血球生成素 (rEPO)，需求量很大，因為它經常用於治療慢性腎臟病、癌症化療和其他疾病引起的貧血。阿爾法依泊汀促進紅血球的合成，有助於減輕貧血症狀並提高患者的生活品質。

市場依適應症分為四類：慢性腎臟病相關貧血（CKD）、癌症相關貧血、HIV相關貧血等。與癌症相關的貧血區隔市場佔主導地位，預計在預測期內將保持其主導地位。重組促紅血球生成素（rEPO）對於治療癌症相關貧血有高的需求。rEPO，特別是 Epoetin Alfa，用於增加紅血球合成，減少輸血需求並改善癌症患者的整體健康。

重組促紅血球生成素市場 - 地理洞察：

從地理來看，市場遍佈北美、拉丁美洲、歐洲、亞太地區和中東非洲。這些地區根據其開展業務的國家進一步劃分。亞太地區對重組促紅血球生成素 (rEPO) 的需求量很大有幾個原因。該地區的許多患者患有與貧血相關的疾病，例如慢性腎臟病和癌症。此外，該地區人口迅速老化和慢性病發病率的增加增加了對 rEPO 作為貧血管理治療選擇的需求。此外，醫療保健基礎設施的改善和醫療技術的進步促使亞太市場 rEPO 的使用量增加。因此，製藥公司正在增加在該地區的業務，以滿足對 rEPO 和其他生物製劑不斷增長的需求。

重組紅血球生成素市場 - 競爭格局：

重組促紅血球生成素（rEPO）在貧血相關疾病的治療中發揮重要作用，面臨激烈的競爭。多家製藥公司參與了rEPO的開發和行銷，創造了競爭環境。該市場由擁有知名品牌和已開發分銷網絡的主要參與者主導。公司透過專注於產品功效、安全性和成本效益來尋求確保競爭優勢。此外，正在進行的研究和開發工作正在改進配方和給藥方法，以提高患者的舒適度和依從性。嚴格的監管合規和專利保護進一步影響競爭者的力量。

最近動態

2023 年2 月，美國食品藥物管理局批准Jesduvroq 片劑（daprodustat）作為第一種口服藥物，用於治療接受至少四個月透析的患者因慢性腎臟病引起的貧血（紅血球計數低） 。Jesduvroq 未被批准用於透析患者以外的任何人。FDA 批准的其他治療方法包括注射到血液中或透過皮膚給藥。

調查的主要特徵

  • 這份關於重組促紅血球生成素市場的研究報告提供了以 2022 年為基準年的市場規模、複合年增長率 (CAGR %)、估計和預測 (2023-2030)。
  • 本研究報告讓客戶深入了解重組紅血球生成素市場的最新發展。
  • 本研究報告闡明了各個區隔市場/國家的潛在成長機會，並解釋了重組促紅血球生成素市場有吸引力的投資主張矩陣。
  • 確定重組促紅血球生成素市場的新投資機會、現有參與者面臨的挑戰以及永續成長因素
  • 研究範圍詳細討論了重組促紅血球生成素市場規模、預測、複合年增長率以及 COVID-19 對市場動態的影響。它還涵蓋了對新冠疫情後重組促紅血球生成素市場的詳細見解。
  • 為了向本報告的用戶提供重組促紅血球生成素市場的全面了解，本報告也對重組促紅血球生成素市場的競爭格局和主要創新者進行了分析。
  • 該研究涵蓋了根據市場規模、成長率和吸引力對所有行業領域進行基準測試的成長前景映射分析。
  • 主要市場參與者的詳細公司簡介可協助您了解在重組促紅血球生成素市場營運的公司的財務資訊和策略舉措。
  • 此外，該報告還揭示了全球和區域市場主要參與者的重要收購和併購、聯盟和合資企業、新產品發布、研發以及區域擴張。
  • 《全球重組促紅血球生成素市場報告》面向該產業的各個利害關係人，主要是供應商、投資者、新進業者、經銷商和財務分析師。

目錄

第1章 基因重組促血紅細胞生長素市場概要

  • 調查範圍
  • 市場估計年數

第2章 摘要整理

  • 市場明細
  • 競爭考察

第3章 基因重組促血紅細胞生長素的主要市場趨勢

  • 基因重組促血紅細胞生長素的市場促進因素
  • 基因重組促血紅細胞生長素阻礙市場要素
  • 基因重組促血紅細胞生長素的市場機會
  • 基因重組促血紅細胞生長素市場未來趨勢

第4章 基因重組促血紅細胞生長素產業調查

  • PEST分析
  • 波特的五力分析
  • 成長預測的製圖
  • 法規結構的分析

第5章 基因重組促血紅細胞生長素市場:COVID-19感染疾病的影響分析

  • 新型冠狀病毒感染疾病前的影響分析
  • 新型冠狀病毒感染疾病後的影響分析

第6章 基因重組促血紅細胞生長素的市場形勢

  • 基因重組促血紅細胞生長素市場佔有率分析，2022年
  • 各主要製造商的明細資料
    • 確立的企業的分析
    • 新興企業的分析

第7章 基因重組促血紅細胞生長素市場- 各類型

  • 概要
    • 各類型市場區隔佔有率分析
    • 紅血球生成素Alpha
    • Darbe Poetin Alpha

第8章 基因重組促血紅細胞生長素市場- 各適應症

  • 概要
    • 各適應症各市場區隔佔有率分析
    • 慢性腎臟病(CKD)伴隨的貧血
    • 癌症相關的貧血
    • HIV相關貧血
    • 其他

第9章 基因重組促血紅細胞生長素市場- 各最終用途

  • 概要
    • 各最終用途市場區隔佔有率分析
    • 醫院和診療所
    • 透析中心
    • 腫瘤中心
    • 其他

第10章 基因重組促血紅細胞生長素市場-各地區

  • 簡介
  • 北美
    • 概要
    • 北美的基因重組促血紅細胞生長素的主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概要
    • 歐洲的基因重組促血紅細胞生長素的主要製造商
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 其他
  • 亞太地區(APAC)
    • 概要
    • 亞太地區的基因重組促血紅細胞生長素的主要製造商
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 其他
  • 南美
    • 概要
    • 南美的基因重組促血紅細胞生長素的主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲
    • 概要
    • 中東及非洲的基因重組促血紅細胞生長素的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第11章 主要供應商分析- 基因重組促血紅細胞生長素產業

  • 競爭儀表板
  • 企業簡介
    • Amgen Inc.
    • Johnson &Johnson
    • LG Chem Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Celltrion Inc.
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • Biocon Limited
    • Sandoz International GmbH
    • Intas Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • 3SBio Inc.
    • CJ CheilJedang Corporation
    • BioSidus SA

第12章 分析師的全方位展望

Product Code: ANV1533

REPORT HIGHLIGHT

Recombinant Erythropoietin Market size was valued at USD 6,851.28 Million in 2022, expanding at a CAGR of 2.1% from 2023 to 2030.

Recombinant erythropoietin (rEPO) is a genetically modified type of erythropoietin, a hormone generated normally in the kidneys that controls red blood cell synthesis. rEPO is created through biotechnology, often using mammalian cells. It possesses the same form and function as endogenous erythropoietin and is utilized for treating anemia-related illnesses including chronic kidney failure, cancer-related anemia, and anemia caused by certain medicinal therapies. rEPO increases oxygen-carrying capacity in the blood by promoting the synthesis of red blood cells, enhancing energy levels, and minimizing the requirement for blood transfusions in patients with anemia.

Recombinant Erythropoietin Market- Market Dynamics:

Rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy to propel market demand

The rising frequency of chronic kidney disease (CKD) and the necessity for efficient anemia therapy is driving demand for recombinant erythropoietin (rEPO). Anaemia is common in CKD patients due to decreased erythropoietin production. rEPO, also known as Epoetin Alfa, is used to increase red blood cell formation, easing anemia symptoms and minimizing the requirement for blood transfusions. As the worldwide prevalence of CKD climbs owing to reasons such as aging populations and lifestyle changes, the healthcare sector's need for rEPO as a vital therapeutic option for anemia treatment in CKD patients grows.

Recombinant Erythropoietin Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Recombinant Erythropoietin market is estimated to grow annually at a CAGR of around 2.1% over the forecast period (2023-2030)
  • The Recombinant Erythropoietin industry is projected to grow at a significant rate due to the rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy
  • Based on Type segmentation, Epoetin Alfa was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Cancer Related Anemia was the leading type in 2022
  • On the basis of region, Asia Pacific was the leading revenue generator in 2022

Recombinant Erythropoietin Market- Segmentation Analysis:

The Global Recombinant Erythropoietin Market is segmented on the basis of Type, Indication, End-Use, and Region.

The market is divided into two categories based on Type: Epoetin Alfa, Darbepoetin Alfa. Epoetin Alfa, a kind of recombinant erythropoietin (rEPO), is in high demand since it is frequently used to treat anemia caused by chronic kidney disease, cancer chemotherapy, and other medical diseases. Epoetin Alfa promotes red blood cell synthesis, which helps to reduce anemia symptoms and enhance patients' quality of life.

The market is divided into four categories based on Indication: Anemia Associated with Chronic Kidney Disease (CKD), Cancer Related Anemia, HIV-Associated Anemia, Others. The Cancer Related Anemia sector dominates the market and is likely to maintain its dominance during the forecast period. In the treatment of cancer-related anemia, recombinant erythropoietin (rEPO) is in great demand. Patients taking chemotherapy for cancer often have a reduction in red blood cell formation, resulting in anemia. rEPO, especially Epoetin Alfa, is used to increase red blood cell synthesis, lowering the need for blood transfusions and increasing the general well-being of cancer patients.

Recombinant Erythropoietin Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Several reasons contribute to the high demand for recombinant erythropoietin (rEPO) in the Asia Pacific area. A considerable patient population in the area suffers from anemia-related illnesses such as chronic renal disease and cancer. Furthermore, the region's rapidly aging population and rising frequency of chronic illnesses boost demand for rEPO as a treatment option for anemia management. Furthermore, improving healthcare infrastructure as well as medical technology improvements led to the increased usage of rEPO in the Asia Pacific market. As a consequence, pharmaceutical firms are increasing their presence in the area to address the increasing demand for rEPO and other biologics.

Recombinant Erythropoietin Market- Competitive Landscape:

Because of its critical function in treating anemia-related disorders, recombinant erythropoietin (rEPO) faces severe competition. Several pharmaceutical firms are involved in the development and marketing of rEPO, creating a competitive environment. The market is dominated by key firms with well-established brands and substantial distribution networks. Companies strive for a competitive advantage by emphasizing product efficacy, safety, and cost-effectiveness. Furthermore, continuous R&D activities seek to enhance formulations and administration modalities, boosting patient comfort and compliance. The competitive dynamics are further influenced by strict regulatory compliance and patent protection.

Recent Developments:

In February 2023, The Food and Drug Administration authorised Jesduvroq tablets (daprodustat) as the first oral medication for anaemia (low red blood cell count) caused by chronic renal disease in individuals who have been receiving on dialysis for at least a four-month period. Jesduvroq is not authorised for non-dialysis patients. Other FDA-approved therapies for this illness are administered through injection into the bloodstream or via the skin.

Key features of the study:

  • This proposed research study on Recombinant Erythropoietin market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Recombinant Erythropoietin market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Recombinant Erythropoietin market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Recombinant Erythropoietin market
  • Impact of COVID-19 on Recombinant Erythropoietin market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Recombinant Erythropoietin market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Recombinant Erythropoietin market, we have also included competitive landscape and key innovator analysis for the Recombinant Erythropoietin market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Recombinant Erythropoietin market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Recombinant Erythropoietin market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET KEY PLAYERS

  • Amgen Inc.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Celltrion Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Biocon Limited
  • Sandoz International GmbH
  • Intas Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • 3SBio Inc.
  • CJ CheilJedang Corporation
  • BioSidus SA

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY TYPE

  • Epoetin Alfa
  • Darbepoetin Alfa

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY INDICATION

  • Anemia Associated with Chronic Kidney Disease (CKD)
  • Cancer Related Anemia
  • HIV-Associated Anemia
  • Others

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY END-USE

  • Hospitals and Clinics
  • Dialysis Centers
  • Oncology Centers
  • Others

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Recombinant Erythropoietin Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Recombinant Erythropoietin Market Snippet by Type
    • 2.1.2. Recombinant Erythropoietin Market Snippet by Indication
    • 2.1.3. Recombinant Erythropoietin Market Snippet by End-Use
    • 2.1.4. Recombinant Erythropoietin Market Snippet by Country
    • 2.1.5. Recombinant Erythropoietin Market Snippet by Region
  • 2.2. Competitive Insights

3. Recombinant Erythropoietin Key Market Trends

  • 3.1. Recombinant Erythropoietin Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Recombinant Erythropoietin Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Recombinant Erythropoietin Market Opportunities
  • 3.4. Recombinant Erythropoietin Market Future Trends

4. Recombinant Erythropoietin Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Recombinant Erythropoietin Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Recombinant Erythropoietin Market Landscape

  • 6.1. Recombinant Erythropoietin Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Recombinant Erythropoietin Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Epoetin Alfa
    • 7.1.3. Darbepoetin Alfa

8. Recombinant Erythropoietin Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 8.1.2. Anemia Associated with Chronic Kidney Disease (CKD)
    • 8.1.3. CancerRelated Anemia
    • 8.1.4. HIV-Associated Anemia
    • 8.1.5. Others

9. Recombinant Erythropoietin Market - By End-Use

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-Use, 2022 & 2030 (%)
    • 9.1.2. Hospitals and Clinics
    • 9.1.3. Dialysis Centers
    • 9.1.4. Oncology Centers
    • 9.1.5. Others

10. Recombinant Erythropoietin Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Recombinant Erythropoietin Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Recombinant Erythropoietin Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Recombinant Erythropoietin Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Recombinant Erythropoietin Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Recombinant Erythropoietin Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Recombinant Erythropoietin Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Amgen Inc.
    • 11.2.2. Johnson & Johnson
    • 11.2.3. LG Chem Ltd.
    • 11.2.4. Dr. Reddy's Laboratories Ltd.
    • 11.2.5. Celltrion Inc.
    • 11.2.6. Pfizer Inc.
    • 11.2.7. Roche Holding AG
    • 11.2.8. Novartis AG
    • 11.2.9. Biocon Limited
    • 11.2.10. Sandoz International GmbH
    • 11.2.11. Intas Pharmaceuticals Ltd.
    • 11.2.12. Teva Pharmaceutical Industries Ltd.
    • 11.2.13. 3SBio Inc.
    • 11.2.14. CJ CheilJedang Corporation
    • 11.2.15. BioSidus SA

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Recombinant Erythropoietin Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Recombinant Erythropoietin Market, by Type 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Recombinant Erythropoietin Market, by Indication 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: End-Use Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End-Use
  • TABLE Global Recombinant Erythropoietin Market, by End-Use 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Recombinant Erythropoietin Market, by Region 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)